Understudied populations with hepatitis C

Hepatology

Volumn 36, Issue 5 I, 2002, Pages

  Strader, Doris B ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; INTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; AUTOIMMUNITY; CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; HEMOGLOBINOPATHY; HEMOPHILIA; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DISEASE; KIDNEY FUNCTION; LIVER DISEASE; MEDICAL DECISION MAKING; POPULATION RESEARCH; PRIORITY JOURNAL; PRISON; PUBLIC HEALTH SERVICE; SUBSTANCE ABUSE; SURVIVAL RATE; THALASSEMIA; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT PLANNING;

ANTIVIRAL AGENTS; CLINICAL TRIALS; HEPATITIS C; HUMANS; PATIENT SELECTION; TREATMENT OUTCOME;

EID: 0036828869     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2002.36991     Document Type: Conference Paper

References (92)

1. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. Lancet 2001;358:958-965.
2. Fried MW, Shiffman ML, Reddy KR, Smith C, Marions G, Goncales F Jr, Haussinger D, et al. Combination of peginterferon alfa-2a plus ribavirin in patients with chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
3. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, et al. Interferon alfa-2a alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-1492.
4. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, et al. Randomised trial of interferon a2b plus ribavirin for 48 weeks or for 24 weeks versus interferon a2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-1432.
5. Cawthorne CH, Rudat KR, Bruton MS, Brown KE, Luxon BA, Janney CG, Fimmel CJ. Limited success of HCV antiviral therapy in United States veterans. Am J Gastroenterol 2002;97:149-155.
6. Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002;136:288-292.
7. Muir AJ, Provenzale D. A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection. J Clin Gastroenterol 2002;34:268-271.
8. Yawn BP, Wollan P, Gassuola L, Kim WR. Diagnosis and 10-year follow up of a community-based hepatitis C cohort. J Fam Pract 2002;51:135-140.
9. Cheung R, Ahmed A. Treating chronic hepatitis C patients with psychiatric disorders: An uphill battle. Am J Gastroenterol 2001;96:3-4 [editorial].
10. Nguyen HA, Miller AI, Dieperink E, Willenbring ML, Tetrick LL, Durfee JM, Ewing SL, et al. Spectrum of disease in U.S. Veteran population with hepatitis C. Am J Gastroenterol 2002;97:1813-1820.
11. National Institutes of Health Consensus Development Conference Panel Statement. Management of hepatitis C. Hepatology 1997;26:2S-10S (suppl 1).
12. Reddy KR, Hoofnagle JH, Tong MJ, Lee WM, Pockros P, Heathcote EJ, Albert D, et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. Hepatology 1999;30:787-793.
13. Howell C, Jeffers L, Hoofnagle. Hepatitis C in African-Americans: Summary of a workshop. Gastroenterology 2000;119:1385-1396.
14. McHutchison JG, Poynard T, Pianko S, Gordon SC, Reid AE, Dienstag J, Morgan T, et al. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. Gastroenterology 2000;119:1317-1323.
15. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Goa F, Moyer LA, Kaslow RA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-562.
16. Anonymous. This Month from the NIH: Virahep-C. Hepatology 2002;36:532-533.
17. Bartenschlaer R, Lohmann V. Novel cell culture systems for the hepatitis C virus. Antiviral Res 2001;52:1-17.
18. Lau J, Standring D. Development of novel therapies for hepatitis C. In: Liang TJ, Hoofnagle JH, eds. Hepatitis C. San Diego: Academic, 2000:453-457.
19. Seeff LB, Lindsay KL, Bacon BR, Kresina TF, Hoofnagle JH. Complementary and alternative medicine in chronic liver disease. Hepatology. 2001;34:595-603.
20. Strader DB, Zimmerman HJ. Complementary and alternative medicine in hepatitis C. In: Liang TJ, Hoofnagle JH, eds. Hepatitis C. San Diego: Academic, 2000:427-451.
21. Strader DB, Bacon BR, Lindsay KL, La Brecque DR, Morgan T, Wright EC, Allen J, et al. Use of complementary and alternative medicine among patients with liver disease. Am J Gastroenterol 2002;97:2391-2397.
22. Basa H, Poli G, Tekkaya C, Arias I. Free radical scavenging and antioxidative properties of'silibin' complexes on microsomal lipid peroxidation. Cell Biochem Funct 1997;15:27-33.
23. Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs 2001;61:2035-2063.
24. Dehmlow C, Erhard J, de Groot H. Inhibition of kupffer cell functions as an explanation of the hepatoprotective properties of silibin. Hepatology 1996;23:749-754.
25. Suzuki H, Ohta T, Takino T, Fujisawa K, Hirayama C. Effects of glycyrrhizin on biochemical tests in patients with chronic hepatitis: Double-blind trial. Asian Med J 1983;26:423-438.
26. Yamamoto M, Uemura T, Nakama S. A fundamental study of chronic hepatitis treated with saiko agents. Proc Symp Wakan-Yaku 1983;16:245-248.
27. Abe Y, Ueda T, Kato T, Kohli Y. Effectiveness of interferon, glycyrrhizin combination therapy in patients with chronic hepatitis C. Nippon Rinsho 1994;52:1817-1822.
28. Liu JP, Manheimer E, Tsutani K, Gluud C. Medicinal herbs for hepatitis C virus infection. Cochrane Database Syst Rev 2001;(4):CD003183.
29. Makris M, Preston FE, Triger DR, Underwood JC, Westlake L, Adelman MI. A randomized controlled trial 'of recombinant interferon-alpha in chronic hepatitis C in hemophiliacs. Blood 1991;78:1672-1677.
30. Hanley JP, Jarvis LM, Andrews J, Dennis R, Hayes PC, Piris J, Lee R, et al. Interferon treatment for chronic hepatitis C infection in hemophiliacs: Influence of virus load, genotype, and liver pathology on response. Blood 1996;87:1704-1709.
31. Rumi MG, Santagostino E, Morfini M, Gringeri A, Tagariello G, Chistolini A, Pontisso P, et al. A multicenter controlled, randomized, open trial of interferonα2b treatment of anti-human immunodeficiency virus-negative hemophilic patients with chronic hepatitis C. Blood 1997;89:3529-3533.
32. Ko JS, Choe YH, Kim EJ, Lee EH, Ja-June J, Jeong Kee S. Interferon alpha treatment of chronic hepatitis C in children with hemophilia. J Pediatr Gastroenterol Nutr 2001;32:41-44.
33. Shields PL, Mutimer DJ, Muir D, Skidmore S, Britnell T, Roberts A, Wilde JT. Combined alpha interferon and ribavirin for the treatment of hepatitis C in patients with hereditary bleeding disorders. Br J Haematol 2000;108;254-258.
34. Sauleda S, Esteban JI, Altisent C, Puig L, Esteban R, Guardia J. Treatment with interferon plus ribavirin in anti-HIV negative patients with congenital coagulation disorders and chronic hepatitis C. Thromb Haemost 2000;83:807-810.
35. Makris M, Baglin T, Dusheiko G, Giangrande PLF, Lee CA, Ludlam CA, Preeston FE, et al. Guidelines on the diagnosis, management and prevention of hepatitis in haemophilia. Haemophilia 2001;7:339-345.
36. Sievert W, Pianko S, Warner S, Bowden S, Simpson I, Bowden D, Locarnini S. Hepatic iron overload does not prevent a sustained virological response to interferon-alpha therapy: A long-term follow-up study in hepatitis C-infected patients with beta thalassemia major. Am J Gastroenterol 2002;97:982-987.
37. Donohue SM, Wonke B, Hoffbrand AV, Reittie J, Ganeshaguru K, Scheuer PJ, Brown D, et al. Alpha interferon in the treatment of chronic hepatitis C infection in thalassaemia major. Br J Haematol 1993;83:491-497.
38. Di Marco V, Lo Iacono O, Almasio P, Ciaccio C, Capra M, Rizzo M, Malizia R, et al. Long-term efficacy of alpha interferon in beta-thalassaemics with chronic hepatitis C. Blood 1997;90:2207-2212.
39. Clemente MG, Congia M, Lai ME, Lilliu F, Lampis R, Frau F, Frau MR, et al. Effect of iron overload on the response to recombinant interferon-alfa treatment in transfusion-dependent patients with thalassemia major and chronic hepatitis C. J Pediatr 1994;125:123-128.
40. Spilopoulou I, Repanti M, Katinakis S, Karana-Ginopoulos A, Papanastasiou DA. Response to interferon alfa-2b therapy in multitransfused children with beta-thalassemia and chronic hepatitis C. Eur J Clin Microbiol Infect Dis 1999;18:709-715.
41. Teller PT, Garson JA, Whitby K, Grant PR, Yardumian A, Hoffbrand AV, Wonke B. Combination therapy with interferon alpha and ribavirin for chronic hepatitis C virus infection in thalassaemic patients. Br J Haematol 1997;98:850-855.
42. Li CK, Chan PK, Ling SC, Ha SY. Interferon and ribavirin as frontline treatment for chronic hepatitis C infection in thalassaemia major. Br J Haematol 2002;117:755-758.
43. Mathurin P, Mouquet C, Poynard T, Sylla C, Benalia H, Fretz C, Thibault V, et al. Impact of hepatitis B and C virus on kidney transplant outcome. Hepatology 1999;29:257-263.
44. Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology 2002;36:3-10.
45. Degos F, Pol S, Chaix ML, Laffitte V, Buffet C, Bernard PH, Degott C, et al. The tolerance and efficacy of interferon-alpha in haemodialysis patients with HCV infection: A multicentre, prospective study. Nephrol Dial Transplant 2001;16:1017-1023.
46. Rostaing L, Modesto A, Baron E, Cisterne JM, Chabannier MH, Durand D. Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. Nephron 1996;74:512-516.
47. Chan TM, Lok AS, Cheng IK, Ng IO. Chronic hepatitis C after renal transplantation: Treatment with interferon. Transplantation 1993;56:1095-1098.
48. Bruchfeld A, Stahle L, Andersson J, Schvarcz R. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection - A pilot study. J Viral Hepat 2001;8:287-292.
49. Mayer WJ, Hess G, Gerken G, Rossol S, Voth R, Manns M, Meyer zum Buschenfelde KH. Treatment of chronic type B hepatitis with recombinant alpha-interferon induces autoantibodies not specific for autoimmune chronic hepatitis. Hepatology 1989;10:24-28.
50. Lisker-Melman M, Di Bisceglie AM, Usala SJ, Weintraub B, Murray LM, Hoofnagle JH. Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. Gastroenterology. 1992;102:2155-2160.
51. Deutsch M, Dourakis S, Manesis EK, Gioustozi A, Hess G, Horsch A, Hadziyannis S. Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy. Hepatology 1997;26:206-210.
52. Bell TM, Bansal AS, Shorthouse C, Sandford N, Powell EE. Low-titer auto-antibodies predict autoimmune disease during interferon-alpha treatment of chronic hepatitis C. J Gastroenterol Hepatol 1999;14:419-422.
53. Taylor C, Burns DA, Wiselka MJ. Extensive psoriasis induced by interferon alfa treatment for chronic hepatitis C. Postgrad Med J 2000;76:365-367.
54. Mavrogiannis C, Papanikolaou IS, Elefsiniotis IS, Psilopoulos DI, Karameris A, Karvountzis G. Ulcerative colitis associated with interferon treatment for chronic hepatitis C. J Hepatol 2001;6:964-965.
55. Mitoro A, Yoshikawa M, Yamamoto K, Mimura M, Yoshikawa Y, Shiroi A, Mochi T, et al. Exacerbation of ulcerative colitis during alpha-interferon therapy for chronic hepatitis C. Intern Med 1993;32:327-331.
56. Fabris P, Betterle C, Floreani A, Greggio NA, de Lazzari F, Naccarato R, Chiaramonte M. Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis. Lancet 1992;340:548 [letter].
57. Recasens M, Aguilera E, Ampurdanes S, Sanchez Tapias JM, Simo O, Casamitjana R, Conget I. Abrupt onset of diabetes during interferon-alpha therapy in patients with chronic hepatitis C. Diabet Med 2001;18:764-767.
58. Bourliere M, Oules V, Perrier H, Mengotti C. Onset of coeliac disease and interferon treatment. Lancet 2001;357:803-804.
59. Adinolfi LE, Durante Mangoni E, Andreana A. Interferon and ribavirin treatment for chronic hepatitis C may activate celiac disease. Am J Gastroenterol. 2001;96:607-608.
60. Fukuyama S, Kajiwara E, Suzuki N, Miyazaki N, Sadoshima S, Onoyama K. Systemic lupus erythematosus after alpha-interferon therapy for chronic hepatitis C: A case report and review of the literature. Am J Gastroenterol 2000;95:310-312.
61. Iyoda K, Kato M, Nakagawa T, Kakiuchi Y, Sugiyasu Y, Fujii E, Fujimoto K, et al. Thrombotic thrombocytopenic purpura developed suddenly during interferon treatment for chronic hepatitis C. J Gastroenterol 1998;33:588-592.
62. Dourakis SP, Deutsch M, Hadziyannis SJ. Immune thrombocytopenia and alpha-interferon therapy. J Hepatol 1996;25:972-975.
63. Landau A, Castera L, Buffet C, Tertian G, Tchernia G. Acute autoimmune hemolytic anemia during interferon-alpha therapy for chronic hepatitis C. Dig Dis Sci 1999;44:1366-1367.
64. Nadir F, Fagiuoli S, Wright HI, Nadir A, Hopp E, Gavaler J, Van Thiel. Rheumatoid arthritis: A complication of interferon therapy. J Okla State Med Assoc 1994;87:228-230.
65. Passos de Souza E, Evangelista Segundo PT, Jose FF, Lemaire D, Santiago M. Rheumatoid arthritis induced by alpha-interferon therapy. Clin Rheumatol 2001;20:297-299.
66. Pittau E, Bogliolo A, Tinti A, Mela Q, Ibba G, Salis G, Perpignano G. Development of arthritis and hypothyroidism during alpha-interferon therapy for chronic hepatitis C. Clin Exp Rheumatol 1997;15:415-419.
67. Garcia-Buey L, Garcia-Monzon C, Rodriguez S, Borque MJ, Garcia-Sanchez A, Iglesias R, DeCastro M, et al. Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C. Gastroenterology 1995;108:1770-1777.
68. Shindo M, Di Bisceglie AM, Hoofnagle JH. Acute exacerbation of liver disease during interferon alfa therapy for chronic hepatitis C. Gastroenterology 1992;102:1406-1408.
69. Fong TL, Valinluck B, Govindarajan S, Charboneau F, Adkins RH, Redeker AG. Short-term prednisone therapy affects aminotransferase activity and hepatitis C virus RNA levels in chronic hepatitis C. Gastroenterology 1994;107:196-199.
70. Bellary S, Schianto T, Hartman G. Chronic hepatitis with combined features of autoimmune chronic hepatitis and chronic hepatitis C: Favorable response to prednisone and azathioprine. Ann Intern Med 1995;123:32-34.
71. Tran A, Benzaken S, Yang G, Schneider S, Doglio A, Rampal A, Rampal P. Chronic hepatitis C and autoimmunity: Good response to immunosuppressive treatment. Dig Dis Sci 1997;42:778-780.
72. Lenzi M, Bellentani S, Saccoccio G, Muratori P, Masutti F, Muratori L, Cassani F, et al. Prevalence of non-organ-specific autoantibodies and chronic liver disease in the general population: A nested case-control study of the Dionysos cohort. Gut 1999;45:435-441.
73. Schiano TD, Te HS, Thomas RM, Hussain H, Bond K, Black M. Results of steroid-based therapy for the hepatitis C-autoimmune hepatitis overlap syndrome. Am J Gastroenterol 2001;96:2984-2991.
74. Soza A, Everhart JE, Ghany MG, Doo E, Heller T, Promrat K, Park Y, et al. Neutropenia during combination therapy of alpha interferon and ribavirin for chronic hepatitis C. Hepatology (in press).
75. Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002;8:350-355.
76. Davis GL, Balart LA, Schiff ER, Lindsay KL, Bodenheimer HC, Perrillo RP, Carey W, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized controlled trial. N Engl J Med 1990;321:1501-1506.
77. Talal AH, Weisz K, Hau T, Kreiswirth S, Dieterich D. A preliminary study of erythropoietin for anemia associated with ribavirin and interferon-alpha. Am J Gastroenterol 2001;96:2802-2804.
78. Devine EB, Kowdly KV, Veenstra DL, Sullivan SD. Management strategies for ribavirin-induced hemolytic anemia in the treatment of hepatitis C: Clinical and economic implications. Value Health 2001;4:376-384.
79. Renault P, Hoofnagle JH, Park Y, Mullen KD, Peters M, Jones DBR, Jones EA. Pscyhiatric complications of long-term interferon alfa therapy. Arch Intern Med 1987;147:1577-1580.
80. Janssen HL, Brouwer JT, van der Mast RC, Schalm SW. Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol 1994;21:241-243.
81. Mulder RT, Ang M, Chapman B, Ross A, Stevens IF, Edgar C. Interferon treatment is not associated with a worsening of psychiatric symptoms in patients with hepatitis C. J Gastroenterol Hepatol 2000;15:300-303.
82. Schramm TM, Lawford BR, Macdonald GA, Cooksley WG. Sertraline treatment of interferon-induced depressive disorder. Med J Austr 2000;173:359-361.
83. Kraus MR, Schafer A, Faller H, Csef H, Scheurlen M. Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. Aliment Pharmacol Ther 2002;16:1091-1099.
84. Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, Greiner K, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001;344:961-966.
85. Zdilar D, Franco-Bronson K, Buchler N, Locala JA, Younossi Z. Hepatitis C, interferon alfa, and depression. Hepatology 2000;31:1207-1211.
86. Ho SB, Nguyen H, Tetrick LL, Opitz GA, Basara ML, Diepetink E. Influence of psychiatric diagnoses on interferon-a treatment for chronic hepatitis C in a veteran population. Am J Gastroenterol 2001;96:157-164.
87. Cheung RC, Ahmed A. Treating chronic hepatitis patients with psychiatric disorders: An uphill battle. Am J Gastroenterol 2001;96:3-4 [editorial].
88. Shakil AO, Di Bisceglie AM, Hoofnagle JH. Seizures during alpha interferon therapy. J Hepatol 1996;24:48-51.
89. Cheung RC, Hanson AK, Maganti K, Keeffe EB, Matsui SM. Viral hepatitis and other infectious diseases in a homeless population. J Clin Gastroenterol 2002;34:476-480.
90. Ruiz JD, Molitor F, Sun RK, Mikanda J, Facer M, Colford JM Jr, Rutherford GW, et al. Prevalence and correlates of hepatitis C virus infection among inmates entering the California correctional system. West J Med 1999;170:156-160.
91. Vlahov D, Nelson KE, Quinn TC, Kendig N. Prevalence and incidence of hepatitis C infection among male prison inmates in Maryland. Eur J Epidemiol 1993;9:566-569.
92. Spaulding A, Greene C, Davidson K, Schneidermann M, Rich J. Hepatitis C in state correctional facilities. Prev Med 1999;28:92-100.